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earning the
oints of COMPASS-HF
ssessing Implantable Hemodynamic
onitoring in Heart Failure Patients*
ohn R. Teerlink, MD, FACC, FAHA, FESC
an Francisco, California
Every [person] has to learn the points of COMPASS again
as often as he awakes, whether from sleep or any abstraction.
Not till we are lost, in other words, not till we have lost the
world, do we begin to find ourselves, and realize where we
are and the infinite extent of our relations.
—Henry David Thoreau [emphasis added] (1)
he litany of numbers is so frequently proclaimed that they
ay be losing their impact—over 5 million patients, more
han 1 million hospital discharges, more than $33 billion in
nnual estimated cost, almost $18 million of which is related
o hospitalization costs (2)—yet it remains clear that heart
ailure is one of the most significant and growing medical
roblems in the U.S. The irony is that the 175% increase in
eart failure hospitalizations during the last 25 years (2) has
ccurred in the context of marked advancements in our
See page 1073
nderstanding of the pathophysiology and treatment of
eart failure, where volume overload or redistribution plays
central role in decompensation and resultant hospitaliza-
ion. One would think that detecting volume overload
efore it resulted in decompensation sufficient to warrant
ospitalization would not be a diagnostic challenge, yet the
tandard tools of the physical examination (3) have re-
ained inadequate to stem this rising tide. Consequently,
onsiderable efforts have been expended to apply more
ontemporary diagnostic tools to this problem.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ational Institutes of Health and the Department of Veterans Affairs; and has
eceived honoraria from and/or has been/is a consultant for Abbott Laboratories,
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esearch, Myogen, NovaCardia, Protein Design Labs, Scios, Inc., and Wyeth.Multiple different approaches have been taken to reduce
ospitalizations for heart failure (4). Most studies of ther-
peutic interventions during hospitalization for heart failure
ave shown no effect on rehospitalization (5–7), although ul-
rafiltration showed significant reductions in rehospitalization
s a secondary end point (8), and the beneficial effects of
ischarging patients on beta-blockers has been emphasized
n observational studies (9). Heart failure management
rograms generally seem to reduce hospitalizations (10),
lthough the ability to extend the results to the community
as been questioned. Other studies have focused on specific
iagnostic tools to guide therapy. In one small study,
atients randomized to B-type natriuretic peptide–guided
herapy had fewer hospitalizations for heart failure (11),
lthough other studies have not been as favorable. Tele-
onitoring has many advantages, allowing for frequent
cheduled as well as patient-initiated evaluations (12) and
exibility to assess symptoms and a variety of signs. A recent
tudy using telephonic monitoring of body weight showed
hat increases in body weight predicted heart failure hospi-
alizations (13); however, a previous study using the same
echnology was not able to show any improvement in
ospitalizations of patients managed with the device, per-
aps because of a 56.2% reduction in 6-month mortality in
he monitored patients (14). Other methods to assess
hanges in body fluid have used the principle of impedance
o estimate changes in fluid status in patients either through
xternal (15) or internal (16) measurements, but their
ffectiveness in reducing hospitalizations has yet to be
hown. In this clinical context, another technology was
eveloped that directly measured intracardiac pressures, the
mplantable continuous hemodynamic monitor.
In this current issue, Bourge et al. (17) present the results
f the landmark COMPASS-HF (Chronicle Offers Man-
gement to Patients with Advanced Signs and Symptoms of
eart Failure) study, a study of 274 patients, all of whom
nderwent placement of an implantable continuous hemo-
ynamic monitor (ICHM) and were subsequently random-
zed to an ICHM-guided management strategy (n  134)
r control group (n  140) follow-up. The study did not
eet the primary efficacy end point of reduction in the rate
f heart failure–related events, but it provides encouraging
ignals and many lessons for future studies. The ICHM in
OMPASS-HF measures absolute right ventricular pres-
ures and applies an algorithm to estimate pulmonary artery
iastolic pressures, which have been shown to correlate well
ith pulmonary capillary wedge pressure (18). The system
onsists of 3 components: 1) a programmable device similar
n appearance and implantation technique to a pacemaker
ulse generator; 2) a transvenous lead positioned in the right
entricular outflow tract or septum; and 3) a small external
evice carried by the patient, which measures barometric
ressure to correct the pressure monitor values.
The patients enrolled in COMPASS-HF comprise aeasonable target population with symptomatic heart failure
(
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lass III/IV) on optimal medical therapy and a recent
ospitalization for heart failure. The inclusion of both
ystolic dysfunction and diastolic heart failure patients is of
articular interest and acknowledges the importance of patients
ith diastolic heart failure in this population. All of the
atients in the study had a device implanted and transmitted
ata, allowing for twice as much information about the
afety of the device and the relationship between changes in
emodynamics and subsequent outcomes. The high rate of
aseline beta-blocker and angiotensin-converting enzyme
nhibitor use indicates that the patients were well treated,
lthough it also unrealistically reduces the event rate of the
rial compared with that expected in the community, where
tilization rates of these agents are lower.
The end points of the study reflect the need to show that
ew devices are both safe and effective. The safety end
oints were met in COMPASS-HF, with a system-related
omplication-free rate of 91.5%, providing 95% confidence
hat the rate was not below 88.7%, with no occurrences of
ressure sensor failure. The primary efficacy end point
ompared the rate of heart failure–related events (hospital-
zations, emergency department visits, and urgent clinic
isits requiring intravenous therapy) in the ICHM (0.67 events
er 6 patient-months) with the control group (0.85 events per
patient-months; p  0.33) with confidence intervals that
ncluded a 25% increase and 48% reduction in the rate.
When evaluating the clinical utility to the patient of such
standalone implantable monitoring device, a number of
oints need to be considered. First, the nonsignificant
ifference of 0.18 events per 6 patient-months does not
epresent the full impact on the patient. This ICHM system
s only implanted for monitoring purposes, and thus, the 15
ospitalizations for complications related to the device (0.06
vents per 6 patient-months), as well as the prolonged initial
ospitalizations related to the device in 6 patients (0.02
vents per 6 patient-months), also need to be incorporated
nto the potential risk–benefit analysis. Additionally, every
atient requires 1 hospitalization for the implant procedure
tself (277 events for 1,620 patient-months of randomized
ollow-up or 1.03 events per 6 patient-months). Patients
ere also required to wear an external pressure monitor and
o invest considerable time and effort in the ICHM man-
gement strategy, with almost 25 calls per patient in the
-month period, as well as 28% more frequent changes in
heir therapies compared with the control group. Although
t was reassuring that these frequent changes in therapy did
ot result in increased adverse events, it is also clear from the
tudy that they provided no definitive benefit, as defined in
OMPASS-HF. Finally, in an era of burgeoning device
herapy for the treatment of heart failure, there is an
pportunity cost to using the limited subclavicular implant-
ble “real estate” for a purely diagnostic device.
The COMPASS-HF study was conducted at leading
eart failure centers, using sensitive and frequent measure-
ents of intracardiac hemodynamics, with approximatelyeekly contact with a health care provider; how could the
OMPASS-HF study have failed to meet its efficacy end
oint? The answer to this question provides the bearings for
uture studies in this field. First, one must consider the
ossibility that right-sided hemodynamics do not provide
he requisite information for preventing heart failure hos-
italizations. Perhaps the measures are not accurate enough,
he physicians did not know how to interpret or apply the
ata, or the paradigm of hemodynamic monitoring itself is
awed. Second, prevention of heart failure events relies on
he ability to provide appropriate, timely, and effective
herapy. Additional information from the COMPASS-HF
tudy on the treatment algorithms and implementation of
herapies may provide important insight into the relation-
hip between the therapeutic interventions and clinical
utcomes. These first 2 possibilities seem unlikely, but
hird, and most likely, is that the study design itself may
ave contributed to the inability to show the efficacy of
CHM. The COMPASS-HF investigators were assiduous
n maintaining the single-blind state of the study, such that
he control group received on average almost weekly calls.
atients in COMPASS-HF had approximately 1.8 events
er 6 patient-months before enrollment in the study, a rate
hat decreased by over 50% in the control group. What is the
ppropriate visit frequency in a control group in a management
trategy trial? If the control group does not receive the same
umber of calls or visits, how will observed differences in
anagement strategies be interpreted? A 3-arm trial con-
isting of the intervention arm, a control group balanced for
ealth care interactions, and another control group with
tandard care may address this issue, but how will the
linding to management group assignment be maintained?
daptive trial designs that can account for lower-than-
nticipated event rates can address some of these issues.
The COMPASS-HF trial was a landmark study provid-
ng many lessons for future trials, but perhaps the most
mportant lesson is for clinicians caring for patients with
eart failure: frequent interactions between patients and
ealth care providers, in conjunction with appropriate use of
herapies that improve outcomes, seems to markedly de-
rease heart failure-related events.
eprint requests and correspondence: Dr. John R. Teerlink, San
rancisco Veterans Affairs Medical Center, Cardiology 111C,
150 Clement Street, San Francisco, California 94121-1545.
-mail: john.teerlink@ucsf.edu.
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